David Safronetz, Job E. Lopez, Nafomon Sogoba, Sékou F. Traore’, Sandra J. Raffel, Elizabeth R. Fischer, Hideki Ebihara, Luis Branco, Robert F. Garry, Tom G. Schwan, and Heinz Feldmann
Author affiliations: National Institutes of Health, Hamilton, Montana, USA (D. Safronetz, J.E. Lopez, S.J. Raffel, E.R. Fischer, H. Ebihara, T.G. Schwan, H. Feldmann); University of Bamako, Bamako, Mali (N. Sogoba, S.F. Traore’); Tulane School of Medicine, New Orleans, Louisiana, USA (L. Branco, R.F. Garry); Autoimmune Technologies LLC, New Orleans (L. Branco)
Appendix Figure. A) Confirmation of isolation of Lassa virus (LASV) Soromba-R by using immunoblot analysis of cell pellets and supernatant from LASV Soromba-R-infected Vero E6 cells (lanes 1 and 3) or uninfected controls (lanes 2 and 4) with a LASV nucleoprotein-specific monoclonal antibody. B) Electron micrograph of LASV particles
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.